Atlas Venture Advisors’s Viridian Therapeutics VRDN Stock Holding History

Atlas Venture Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-209,505	Closed	-$5.33M	–	6
2023 Q1	$5.33M	Hold	209,505	–	–	1.15%	3
2022 Q4	$6.12M	Hold	209,505	–	–	2.11%	3
2022 Q3	$4.3M	Hold	209,505	–	–	1.55%	3
2022 Q2	$2.42M	Hold	209,505	–	–	0.77%	6
2022 Q1	$3.87M	Hold	209,505	–	–	0.83%	5
2021 Q4	$4.14M	Hold	209,505	–	–	0.58%	5
2021 Q3	$3.45M	Hold	209,505	–	–	0.41%	7
2021 Q2	$3.83M	Hold	209,505	–	–	0.4%	8
2021 Q1	$3.5M	Hold	209,505	–	–	0.65%	8
2020 Q4	$3.45M	Hold	209,505	–	–	0.77%	8
2020 Q3	$2.45M	Hold	209,505	–	–	0.41%	8
2020 Q2	$3.49M	Hold	209,505	–	–	0.89%	8
2020 Q1	$1.41M	Hold	209,505	–	–	1.91%	7
2019 Q4	$1.51M	Hold	209,505	–	–	2.28%	7
2019 Q3	$2.3M	Hold	209,505	–	–	0.71%	7
2019 Q2	$6.44M	Hold	209,505	–	–	2.67%	4
2019 Q1	$8.77M	Hold	209,505	–	–	4.43%	4
2018 Q4	$9.52M	Buy	+209,505	New	+$12.1M	5.03%	4

Other funds holding VRDN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Atlas Venture Advisors's VRDN Position: Q2 2023 in Review

Atlas Venture Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 209,505 shares — an estimated $5.33M sold.

Atlas Venture Advisors first reported a position in VRDN in Q4 2018 and held it in 18 quarters. The position peaked at $9.52M in Q4 2018. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

Atlas Venture Advisors reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
Atlas Venture Advisors sold 209,505 Viridian Therapeutics shares in Q2 2023, an estimated $5.33M.
Atlas Venture Advisors first reported a position in Viridian Therapeutics in Q4 2018 and held it in 18 quarters.
Atlas Venture Advisors's Viridian Therapeutics position peaked at $9.52M in Q4 2018.
128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on Atlas Venture Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.